Raise capital 1.4 billion Sea King biology heavy to drop to medicine logistics

Sea King creature (000078.　　SZ) February 17 Evening Notice that the company's board of directors to consider the adoption of the "Company's Non-public offering of shares proposal", will not be issued more than 139 million A shares, the issue price is not less than 10.37 yuan/share, the total amount of capital raised not more than 1.443 billion yuan (including the issue of fees).　　The Sea King Bio-raise funds will be used for pharmaceutical business Sunshine Centralized distribution center construction projects, Sea King pharmaceutical solid preparation production line renovation project, Sea King Pharmaceutical Anti-tumor freeze-Dry Preparation workshop construction project and Hangzhou Hai Wang Health Products production line construction project. This non-public offering, the Lion of Sea King Biology is to build "Sunshine concentrated distribution Center", its distribution mode is mainly the distribution business through the integration of social resources, intensive supply chain process, compressed operating costs, standardize the supply channels, the completion of the jurisdiction of the region's leading hospital drug use of centralized distribution work, the Sea King biological business has been in Shandong　　, Henan and other land development and achieved certain results. The announcement said, Sea King Biological plan to invest 1.102 billion yuan, in Shandong Weihai, Shandong Heze, Shandong Zaozhuang, Henan Nanyang, Hubei Xiaogan Five to set up a subsidiary to build Sunshine Centralized distribution center.　　The implementation of the project is a wholly-owned subsidiary of the Sea King Galaxy, in addition to Sea King Bio-raised 1.102 billion yuan, Sea King Galaxy will raise 990 million yuan joint investment.　　Prior to this, the Sea King has in these five cities to varying degrees to start the sun concentrated distribution business, but also in the local pharmaceutical distribution market occupies a certain share, the fund-raising is mainly in these areas of the two-level medical institutions in the promotion of centralized distribution business. The company is expected to be completed, Shandong Weihai, Shandong Heze, Shandong Zaozhuang, Henan Nanyang, Hubei Xiaogan five projects average annual sales income of 1,398,050,000 yuan, 1,465,520,000 yuan, 1,155,170,000 yuan, 2,133,170,000 yuan, 1,859,460,000 yuan.　　Annual net profit amounted to 28.62 million yuan, 26.92 million yuan, 27.13 million yuan 31.24 million yuan, 23.27 million yuan respectively. The announcement indicated that the total duration of the 5 projects was 36 months.　　And the most dynamic recovery period of these projects is Xiaogan, Hubei province, the company expected dynamic investment recovery period (after tax) up to 10.53 years (including construction period), the shortest time in Shandong Zaozhuang Dynamic Investment recovery period (after-tax) 5.29 years (including construction period). Sea King Biology also said that proposed to the subsidiary of Shenzhen Sea King Pharmaceutical Co., Ltd. to increase the capital of not more than 175 million yuan, for the Sea King pharmaceutical solid preparation production line project and anti-tumor freeze-dry workshop project; In addition to the subsidiary of Hangzhou Hai Wang Bioengineering Co.